PMID- 18471359
OWN - NLM
STAT- MEDLINE
DCOM- 20100204
LR  - 20181201
IS  - 1003-0603 (Print)
IS  - 1003-0603 (Linking)
VI  - 20
IP  - 5
DP  - 2008 May
TI  - [Study on protective effects and its mechanism of leflunomide on renal tissue in 
      rat IgA nephropathy model].
PG  - 283-5
AB  - OBJECTIVE: To observe the effects of leflunomide on renal pathology and 
      expression of transforming growth factor-beta1 (TGF-beta1), monocyte chemotaxis 
      peptide 1 (MCP-1) in renal tissue of experimental IgA nephropathy in rat. 
      METHODS: IgA nephropathy model was reproduced in rats. They were randomly divided 
      into leflunomide group, prednisone group, nephropathy control group, and normal 
      control group. The deposition of immunocomplex in renal tissue and degree of 
      mesangial matrix hyperplasia in mesangial region were detected by 
      immunofluorescence and light microscope; the level of expression of gene and 
      protein of TGF-beta1 and MCP-1 in renal tissue were determined by 
      immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) 
      methods. RESULTS: Compared with model group, leflunomide lessened the deposit of 
      immunocomplex in renal tissue, alleviated the hyperplasia of mesangial matrix 
      (all P<0.01). Leflunomide could also inhibit the expression of TGF-beta1, MCP-1 
      at the level of gene and protein in renal tissue (P<0.05 or P<0.01). CONCLUSION: 
      Leflunomide can decrease the deposit of immunocomplex, down regulate the 
      expression of TGF-beta1, MCP-1 in kidney, diminish local inflammatory reaction, 
      relieve hyperplasia of mesangial matrix, related the process of nephrotic 
      fibrosis, and protect renal function.
FAU - Tang, Ying
AU  - Tang Y
AD  - Department of Nephrology, The Third Affiliated Hospital of SUN Yat-sen 
      University, Guangzhou 510630, Guangdong, China.
FAU - Lou, Tan-Qi
AU  - Lou TQ
FAU - Wang, Cheng
AU  - Wang C
FAU - Peng, Hui
AU  - Peng H
FAU - Liu, Xun
AU  - Liu X
FAU - Tang, Hua
AU  - Tang H
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
JT  - Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo 
      weizhongbing jijiuyixue
JID - 9887521
RN  - 0 (Chemokine CCL2)
RN  - 0 (Isoxazoles)
RN  - 0 (Transforming Growth Factor beta1)
RN  - G162GK9U4W (Leflunomide)
SB  - IM
MH  - Animals
MH  - Chemokine CCL2/metabolism
MH  - Disease Models, Animal
MH  - Fibrosis
MH  - Glomerulonephritis, IGA/*drug therapy/metabolism/pathology
MH  - Isoxazoles/*pharmacology
MH  - Kidney/*drug effects/metabolism/pathology
MH  - Leflunomide
MH  - Male
MH  - Random Allocation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Transforming Growth Factor beta1/metabolism
EDAT- 2008/05/13 09:00
MHDA- 2010/02/05 06:00
CRDT- 2008/05/13 09:00
PHST- 2008/05/13 09:00 [pubmed]
PHST- 2010/02/05 06:00 [medline]
PHST- 2008/05/13 09:00 [entrez]
PST - ppublish
SO  - Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2008 May;20(5):283-5.